Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Takeover offer to the shareholders of Epigenomics AG

Summit Hero Holding GmbH published further information about the offer on the website www.summit-hero-angebot.de. This includes the approved offer document, which was published on June 8, 2017.

We cannot assume any liability for the content and accuracy of the information provided.

Current information

+++Epigenomics AG: Voluntary public takeover offer by Summit Hero Holding not successful+++

Berlin, July 12, 2017 – Summit Hero Holding GmbH (“bidder”) announced today that, as of expiry of the extended acceptance period at midnight (24:00 CEST) on July 7, 2017, 62.13 percent of Epigenomics outstanding shares have been tendered under the voluntary public takeover offer or were held by or attributed to the bidder. Consequently, the minimum acceptance threshold of 75.0 percent has not been reached.

Announcements

Execution of Irrevocable Undertakings by all Board Members (PDF)

Joint reasoned statement of Executive Board and Supervisory Board of Epigenomics AG as of June 13, 2017 – German version (PDF)

Press Releases

June 14, 2017 – Executive Board and Supervisory Board recommend acceptance of the voluntary public takeover offer (PDF)

June 8, 2017 – Offer document published for the voluntary public takeover offer for Epigenomics AG (PDF)

May 31, 2017 – Epigenomics’ Annual General Meeting: CEO touts takeover offer (PDF)

April 26, 2017 – Blitz F16-83 GmbH to launch takeover offer for Epigenomics AG (PDF)

Publication of Inside Information according to Article 17 MAR

April 26, 2017 – Blitz F16-83 GmbH to launch takeover offer for Epigenomics AG (PDF)